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In the fast-pace of Cancer Research (CR) activities, high throughput 
technologies and accumulation of data by NGS and –OMICS in general, 
some milestones in our understanding of cancer may easily skip our 
attention. This year marks 50 years from the assignment of two Nobel 
Prizes for CR in 1966: to Peyton Rous and Charles Huggins [1-4]. Some 
reflections may be worthier, since they also impinge on today’s state of 
affair in CR. First of all, the two certainly appeared as an “odd couple” in 
1966 [5]. A celebrated virologist and immunologist from the Rockefeller 
University (Institute at that time), the work of Rous -87 at that time- 
seemed to have little to share with the clinical breakthroughs just realized 
by the Canadian endocrinologist Huggins at the University of Chicago. 
Although coming from widely different areas of medicine (microbiology 
and surgery) they both knew and highly respected each other [2]. 
Furthermore, these two CR giants certainly overlapped in their belief that 
research intuition and scientific ingenuity and discovery would be at the 
basis of any further development in science.
Rous discovery was made the same year he entered Rockefeller (1909), 
when a hen of a particular breed of Plymouth was brought to his attention 
from a farmer in view of a prominent wing sarcoma. Not only could he 
transfer the tumour with isolated cells, but also with a cell-free extract 
and after ultra-filtration, thus excluding transfer of entire cells (or even 
bacteria) and strongly implicating presence of an infecting virus. The initial 
paper was published in 1911 by the Journal of Experimental Medicine 
and followed by several additional reports characterizing the system [6-7]. 
However, Rous group could never isolate the responsible virus, now called 
RSV, and finally shifted in 1915 to other relevant biomedical subjects of 
research. Still, he returned to viral oncology in the 1930’s by studying a 
different virus: the Papilloma Virus in rabbits, that Shope had isolated 
a few years earlier [8]. Only several years later, starting in the mid 50s, 
a systematic study of RSV tumorigenesis in vivo and transformation of 
chicken cells in vitro was initiated in the laboratory of R. Dulbecco in 
California and with great pioneers such H. Rubin, H. Temin, H. Hanafusa, 
P. Vogt, P. Duesberg, M. Bishop, H. Varmus, R. Weiss, J. Svoboda etc. (for 
excellent reviews of this field, see [9,10]). This initially led to the discovery 
of reverse transcriptase by Temin’s and Baltimore’s laboratories and 
finally to the isolation of the first oncogene, baptised SRC, from RSV viral 
genome in the laboratory of Bishop-Varmus: also these discoveries were 
awarded by the Nobel Prize (in 1975 and 1989 [11,12] ) and most of all the 
birth of a new era called molecular oncology.
The seminal discovery of C. Huggins was published 30 years later in 
1941, when he reported with colleague Clarence Hodges that androgen 
ablation -either by surgical castration or by giving estrogens (stilbestrol) 
as androgen antagonists- causes prostate cancer (PCa) atrophy and 
regression. Starting from the first attempt, this approach has been very 
successful, since it allowed patients with metastatic PCa to immediately 
experience great pain relief and amelioration due to tumour shrinkage 
and final atrophy [3-4]. Today, we know that PCa can be a rather indolent 
disease, therefore controllable by Androgen Depletion Therapy (ADT). 
Unfortunately, in many cases ADT or surgical castration is followed by 
metastatic castration resistant prostate cancer (mCRPC), a condition for 
which we don’t have today curative solutions [13]. To conclude the parable 
about the odd couple in 1966 Nobel sharing, the following half Century 
has shown how the two discoveries have much assonance, and yet they 
present today common difficulties or open questions [5,14,15].
What we call Molecular Oncology was created from the seminal 
discovery of P. Rous in 1911 and the patient ingenuity of H. Varmus and 
M. Bishop several years later (among many others) who finally provided 
a rational interpretation of the molecular intricacies of cancer cells. The 
most acclaimed of such new molecular interpretations is the one proposed 
as “Hallmarks of Cancer” (HoC) by D. Hanahan and R. Weinberg in 
2000 and 2011 and as an even more detailed “mosaic” of every aspect 
of molecular-cancer in the 2014 book “The Biology of Cancer” [16-18]. 
Unquestionably, such molecular reform started from Rous seminal 
intuition, had the great merit–both historical and epistemological- to put 
under the same umbrella the many disparate pathologies (at least 50 of 
them), that we call cancer. Yet and as later discussed, it is clear today that 
also this approach or model should be revised [14,15].
As previously discussed, today we can progress at much faster pace in 
view of accelerated technological advances in the so called NGS Era [15], 
although a detailed description of cancer in general- and PCa specific- 
alterations had been initiated also in the pre-NGS era [19]. Since essentially 
every human cancer has been affected by this kind of revolution, what are 
today’s implications for Huggins discoveries and PCa in particular? 1. PCa 
sets itself apart from other neoplasms since it shows the lowest number 
of point-mutations or SNVs (single nucleotide variants) among human 
cancers (in the order of .33/1.4 per MegaBase) [20,21]. This already 
contradicts a long-accepted tenet of molecular oncology: that cancer may 
be just caused by accrual/accumulation of point mutations in essential 
regulators of cell-cycle/cell-control (so called cancer-drivers) [14,22,23]. 
Interestingly, it also agrees with the consistently and almost stubbornly 
defended opinion of Rous that point-mutations have little relevance in 
cancer onset and progression [2,7]. 2. Lack of point mutations is amply 
compensated in PCa by extensive presence of variations in copy numbers 
(CNAs): among amplifications, MYC and AR genes are the most frequent, 
while several regions believed to contain TSGs (tumor suppressor 
genes) are also often deleted (NKX3, PTEN, CDKN1B, RB1, TP53) 
[24]. 3. Major alterations of PCa genomes appear to be dichotomized, 
as approximately 50% contain rearrangements between the TMPRSS2 
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Take-home messages of the Rous-Huggins parable and parallelism both 
in their initial successes and present day stalling suggest that we should 
not sit on our laurels and that reappraisal of these fields is called for. A 
new effort should be made in order to understand the HoC paradox/
contradictions, i.e. tumour heterogeneity and so-called oncogene-
addiction. At the same time, revision of ADT is also logically requested, 
since in a considerable number of patients it will naturally select for 
deadly mCRPC [14,33]. From wherever they are, even Rous and Huggins 
will applaud to new research on fundamental causes of cancer, knowing 
the experimental faith of the Rockefeller Virologist and the motto’s of the 
Chicago U. Urologist: “Discovery is our business” and “Make damn good 
discoveries!”. 
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contributed to decipher a plethora of genetic and genomic aberrations, 
which distinguish cancer in general and PCa in particular. Can this 
paradigm or parable be extended even further to the present day 
obvious “difficulties” that characterize both molecular oncology (and 
the “hallmarks” vision [17]) and the therapeutic approaches for mCRPC 
(which are very limited since this form of PCa becomes rapidly incurable) 
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P. Rous a few years after the discovery of RSV.                              C. Huggins working in the laboratory
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